Cannabidiol for epilepsy expected to be available within 6 weeks: industry news round-up

This week’s industry news round-up reveals the latest updates including a new medicine for migraine, a rescheduling of cannabidiol for epilepsy and a successful Phase III trial for neuromyelitis optica spectrum disorder. Find out more about our selection of the highlights below. Our selection of the highlights includes: Emgality™ receives marketing authorization for the prevention of migraine Alexion reveals positive results for Soliris® in patients with neuromyelitis optica spectrum disorder GW Pharmaceuticals announces DEA reschedule of Epidiolex® for epilepsy Emgality™ receives marketing authorization for the prevention of migraine The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended...